Consistently, combined VEGF- or VEGF-R- and CXCR4 antagonism prolongs survival of mice bearing orthotopically xenografted GBM as compared to only VEGF/VEGF-R-targeted mice (87, 118, 120). The gene discussed is CXCR4; the disease is glioblastoma.